

**ASSEMBLY OF THE CYTOLYTIC ALTERNATIVE PATHWAY  
OF COMPLEMENT FROM 11 ISOLATED PLASMA PROTEINS\***

BY ROBERT D. SCHREIBER‡ AND HANS J. MÜLLER-EBERHARD§

*From the Department of Molecular Immunology, Research Institute of Scripps Clinic, La Jolla, California  
92037*

It has been shown recently that the alternative pathway of complement activation can be assembled from six isolated plasma proteins including C3, Factors B and D,  $\beta$ 1H, C3b inactivator, and properdin (1). The functional activity of this mixture has been shown to be comparable to that of the alternative pathway in serum with respect to initiation and amplification. The cytolytic membrane attack pathway is known to be composed of five plasma proteins, C5, C6, C7, C8, and C9 (2). Cells capable of initiating the alternative pathway in serum have been demonstrated to undergo lysis (3–6). The question arose, therefore, as to whether the composite mixture of the isolated alternative pathway proteins and the isolated membrane attack pathway proteins is capable of causing lysis of cells such as rabbit erythrocytes which activate the alternative pathway. It is the purpose of this communication to report that the combination of the 11 isolated proteins in physiological concentrations constitutes an intact alternative pathway with cytolytic activity quantitatively comparable to that of serum.

**Materials and Methods**

*Purified Components.* C3 (7), Factor B (8), Factor D (9), C3b Inactivator (10),  $\beta$ 1H (10), native properdin (11), C5 (7), C6 (12), C7 (12), C8 (13), and C9 (14) were prepared as described elsewhere. The mixture of purified components at physiological concentrations was prepared as follows: C3 (4,500  $\mu$ g/ml) was incubated with  $\beta$ 1H (1,500  $\mu$ g/ml) and C3bINA (102  $\mu$ g/ml) for 30 min at 37° so as to inactivate any C3b contaminant in the C3 preparation. After cooling at 0°C, the remaining eight components were added such that the final protein concentrations were: 1,200  $\mu$ g/ml C3; 200  $\mu$ g/ml Factor B; 2  $\mu$ g/ml Factor D; 470  $\mu$ g/ml  $\beta$ 1H; 34  $\mu$ g/ml C3bINA; 20  $\mu$ g/ml nP; 72  $\mu$ g/ml C5; 64  $\mu$ g/ml C6; 54  $\mu$ g/ml C7, 54  $\mu$ g/ml C8, and 58  $\mu$ g/ml C9.

*Neuraminidase-Treated Sheep Erythrocytes ( $E_s$ -NA).*  $E_s$ -NA were prepared as described by Pangburn and Müller-Eberhard (5). Sheep erythrocytes suspended in 0.5 M sodium acetate buffer pH 5.5 containing 0.9% NaCl and 0.1% CaCl<sub>2</sub> were incubated for 60 min, at 37°C with 10 U/ml of *Vibrio cholerae* neuraminidase (Behring Diagnostics, Somerville, N. J.) and then washed and stored in DGVB.

*C4-Depleted Human Serum.* C4-depleted human serum was prepared by immuneadsorption on columns of Sepharose 4B (Pharmacia Fine Chemicals) to which the IgG fraction of monospecific goat anti C4 serum had been coupled as described previously (4).

*Buffers.* VB: isotonic veronal buffered saline pH 7.4; Mg-GVB: VB containing 0.1% gelatin and 1.2 mM MgCl<sub>2</sub>; DGVB: one-half physiological ionic strength VB containing 0.1% gelatin, 0.15 mM CaCl<sub>2</sub>, 0.5 mM MgCl<sub>2</sub> and 2.5% Dextrose.

\* Supported by U. S. Public Health Service grants AI 07007 and HL 16411; Publication 1620.

‡ Recipient of an Established Investigatorship (No. 77 202) from the American Heart Association.

§ Cecil H. and Ida M. Green Investigator in Medical Research, Research Institute of Scripps Clinic.

*Sodium Dodecyl Sulfate (SDS)-Polyacrylamide Gel Electrophoresis.* SDS-polyacrylamide gel electrophoresis was performed in 7% polyacrylamide gels using the method of Weber and Osborn (15).

*Lysis of Erythrocytes by the Alternative Pathway.* This process was performed as described elsewhere (4). Total reaction mixtures of 160  $\mu$ l contained varying amounts of either C4-depleted serum or purified components, 1.2 mM MgSO<sub>4</sub>, Mg-GVB, and 10<sup>7</sup> erythrocytes suspended in Mg-GVB. After incubation for 10 min at 37°C, lysis was stopped by addition of 1 ml cold Mg-GVB and centrifugation. Hemolysis was determined spectrophotometrically at 412 nm.

*Chemotaxis Assay for Human Polymorphonuclear Leukocytes.* This process was performed using the chemotaxis under agarose method of Chenoweth et al. (16). 1 ED<sub>50</sub> U is defined as that amount of material which elicits one-half of the maximal chemotactic response.

## Results

*Demonstration of the 11 Isolated Proteins.* Fig. 1 shows the eleven isolated proteins as they appear after electrophoresis in sodium dodecyl sulfate containing polyacrylamide gels. All proteins were analyzed at a concentration of  $\cong$  1 mg/ml. Excluding C3, this concentration is higher than the concentration of these proteins in serum. In the case of Factor D, it is 500 times the physiological concentration (17). All proteins except C8 appear as single bands under nonreducing conditions. Factors B (18) and D (18),  $\beta$ 1H (19), C6 (12), C7 (12), and C9 (20) are known to be single chain proteins. Properdin consists of four identical noncovalently bonded polypeptide chains (11, 21). C3 (22, 23), C3bINA (10) and C5 (22) are composed of two disulfide-linked nonidentical chains. C8 consists of two SDS dissociable subunits, the heavier representing the disulfide linked  $\alpha$ - and  $\gamma$ -chains and the lighter constituting the  $\beta$ -chain (13). Inspection of the stained gels indicate 95–99% purity of the isolated proteins.

*The Cytolytic Activity of the 11 Isolated Proteins.* The 11 proteins were admixed at serum concentration: C3, 1,200  $\mu$ g/ml; Factor B, 200  $\mu$ g/ml; Factor D, 2  $\mu$ g/ml; properdin, 20  $\mu$ g/ml; C3bINA, 34  $\mu$ g/ml;  $\beta$ 1H, 470  $\mu$ g/ml; C5, 72  $\mu$ g/ml; C6, 64  $\mu$ g/ml; C7, 54  $\mu$ g/ml; C8, 54  $\mu$ g/ml; and C9 58  $\mu$ g/ml. The solvent was veronal-buffered physiological saline pH 7.4 containing 1.2 mM MgSO<sub>4</sub>. Cells used were rabbit erythrocytes (E<sub>R</sub>), sheep erythrocytes (E<sub>S</sub>), and neuraminidase-treated sheep erythrocytes (E<sub>S</sub>-NA). Fig. 2 shows the dose-related lysis of E<sub>R</sub> and E<sub>S</sub>-NA but not of E<sub>S</sub> by the isolated component mixture. 50% lysis of E<sub>R</sub> was obtained with 13.8  $\mu$ l and of E<sub>S</sub>-NA with 35.5  $\mu$ l of the component mixture. No lysis was observed when in control experiments either the six alternative pathway proteins or the five membrane attack pathway proteins were omitted, or when individual proteins, such as Factor B, C3, or C7 were deleted from the complete mixture. In the absence of activating cells, the component mixture was stable at 37°C with respect to consumption of Factor B, C3, and C5. Also shown in Fig. 2, is the lytic capacity of C4 depleted human serum. The dose-response curves are virtually identical to those obtained with the component mixture, 50% lysis of E<sub>R</sub> was caused by 13  $\mu$ l and of E<sub>S</sub>-NA by 33  $\mu$ l of the serum.

*The Nonessential, Regulatory Role of Properdin in the Lysis of Rabbit Erythrocytes.* Previously reported experiments with properdin-depleted human serum indicated that properdin enhances rabbit erythrocyte lysis but is not essential (4). We have also shown that properdin is not essential for the initiation of the alternative pathway assembled from isolated proteins (1). As shown in Fig. 3, lysis of rabbit erythrocytes by the isolated component mixture proceeds in absence of properdin. 50% lysis was effected by 37  $\mu$ l of mixture without properdin and by 16  $\mu$ l of mixture with properdin.




FIG. 1. Proteins of the cytolytic alternative pathway. 20- $\mu$ g samples of each protein were subjected to SDS-polyacrylamide gel electrophoresis in 7% gels under nonreducing conditions. Gels were stained with Coomassie Blue dye R250. Proteins C3 through properdin (P) constitute the components of the alternative pathway of activation. Proteins C5 through C9 constitute the components of the membrane attack pathway.




FIG. 2. Assembly of an intact cytolytic alternative pathway from 11 purified proteins. 160  $\mu$ l reaction mixtures containing  $10^7$  erythrocytes, Mg-GVB, and varying amounts of either C4-depleted serum (●) or the mixture of 11 purified components (□) (see Materials and Methods) were incubated for 10 min at 37°C. Reactions were stopped by addition of 1 ml cold Mg-GVB and centrifugation. Lysis was determined spectrophotometrically at 412 nm. Shown are the dose-response curves for lysis of rabbit erythrocytes (—) neuraminidase-treated sheep erythrocytes (----), and untreated sheep erythrocytes (-·-·-).

*Generation of chemotactic activity in the isolated system.* When the mixture of isolated components was incubated with 5 mg/ml zymosan for 45 min at 37°C chemotactic activity for polymorphonuclear leukocytes could subsequently be detected (Table I). C4-depleted serum after treatment with zymosan also contained chemotactic activity but fourfold less than the mixture.




FIG. 3. The nonessential role of properdin in the alternative pathway. Dose-response curves for rabbit erythrocyte lysis using the isolated component mixture either containing (○) or lacking (●) native properdin were generated as described in Fig. 2.

TABLE 1  
*Zymosan-Induced Generation of Chemotactic Activity in the Purified Component Mixture or in C4-Depleted Human Serum*

System	Chemotactic Activity (ED <sub>50</sub> /ml)	
	+ Zymosan	+ Buffer
Purified components	2,128	<100
C4-depleted human serum	588	<100

### Discussion

This is the first demonstration of the generation of cytolytic activity of the alternative pathway assembled entirely from isolated proteins. That the alternative pathway of complement activation can be assembled from C3, Factors B and D, and the three known regulatory factors has been documented (1). Whether the interaction of this activation system with the membrane attack system requires additional factors had not been critically evaluated heretofore. The results of this study indicate that no factors other than the 11 isolated proteins are required for the lysis of the alternative pathway activators: rabbit erythrocytes and neuraminidase-treated sheep erythrocytes. The quantitative similarity of the dose-response curves obtained with the component mixture and with C4-depleted serum further support our conclusion. No immunoglobulin requirement was found for the two cytolytic systems studied. We do not wish to imply on the basis of these results, that other cytolytic systems involving the alternative pathway may not need additional factors. It is known, for instance, that the cytolytic function of the pathway with regard to measles virus-infected cells is dependent on IgG with anti-measles virus specificity (24). And the complement-dependent lysis of gram-negative bacteria appears to involve lysozyme and perhaps other factors in addition to the membranolytic complex of complement (25, 26). Whether the results of this study have general validity for alternative pathway-dependent cytolysis necessitates a systematic investigation using the isolated component system described here and various cellular activators of the pathway.

### Summary

The known cytolytic function of the alternative pathway in serum was quantitatively reproduced by combining 11 isolated plasma proteins at their respective serum

concentrations. These proteins are: C3, Factor B, Factor D, C3b inactivator,  $\beta$ 1H, native properdin, C5, C6, C7, C8, and C9. In absence of activators of the alternative pathway, this mixture was stable at 37°C as evidenced by lack of consumption of Factor B, C3, and C5. Upon addition of either rabbit erythrocytes or neuraminidase-treated sheep erythrocytes, cell lysis ensued and the extent of lysis was dependent on dose of the component mixture. The dose-response curves obtained with the isolated component mixture and with C4-depleted serum were virtually indistinguishable. Nonactivator erythrocytes (untreated sheep erythrocytes) were not lysed by the component mixture. Deletion of properdin resulted only in a twofold diminution of the hemolytic activity of the component mixture. No immunoglobulin requirement was apparent. These results indicate that the cytolytic systems studied are internally sufficient and capable of coupling the initiation and amplification sequence with the cytolytic membrane attack sequence.

The authors wish to acknowledge the essential technical assistance of Mary Brothers and Lorraine Wood in these studies. We also wish to thank J. G. Rowe for performing the chemotaxis under agarose assays. Furthermore, we wish to acknowledge Doctors M. Pangburn, P. Lessaure, E. Podack, A. Esser, and G. Biesecker of this Laboratory for contributing to the supply of isolated proteins.

*Received for publication 18 September 1978.*

### References

- Schreiber, R. D., M. K. Pangburn, P. H. Lesavre, and H. J. Müller-Eberhard. 1978. Initiation of the alternative pathway complement: Recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. *Proc. Natl. Acad. Sci. U. S. A.* **75**:3948.
- Kolb, W. P., and H. J. Müller-Eberhard. 1975. The Membrane attack mechanism of Complement: isolation and subunit composition of the C5b-9 complex. *J. Exp. Med.* **141**: 724.
- Platts-Mills, T. A. E., and K. Ishizaka. 1974. Activation of the alternative pathway of human complement by rabbit cells. *J. Immunol.* **113**:348.
- Schreiber, R. D., O. Götze, and H. J. Müller-Eberhard. 1976. Alternative pathway of complement: Demonstration and characterization of initiating factor and its properdin-independent function. *J. Exp. Med.* **144**:1062.
- Pangburn, M. K., and H. J. Müller-Eberhard. 1978. Complement C3 convertase: cell surface restriction of  $\beta$ 1H control and generation of restriction of neuraminidase-treated cells. *Proc. Natl. Acad. Sci. U. S. A.* **75**:2416.
- Fearon, D. T. 1978. Regulation by membrane sialic acid of  $\beta$ 1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. *Proc. Natl. Acad. Sci. U. S. A.* **75**:1971.
- Tack, B. F., and Prahl, J. W. 1976. Third component of human complement: purification from plasma and physicochemical characterization. *Biochemistry.* **15**:4513.
- Götze, O., and H. J. Müller-Eberhard. 1971. The C3-activator system: an alternate pathway of complement activation. *J. Exp. Med.* **134**:90s.
- Götze, O., and H. J. Müller-Eberhard. 1974. The role of properdin in the alternate pathway of complement activation. *J. Exp. Med.* **139**:44.
- Pangburn, M. K., R. D. Schreiber, and H. J. Müller-Eberhard. 1977. Human complement C3b inactivator: isolation characterization, and demonstration of an absolute requirement for the serum protein  $\beta$ 1H for cleavage of C3b and C4b in solution. *J. Exp. Med.* **146**:257.
- Götze, O., R. G. Medicus, and H. J. Müller-Eberhard. 1977. Alternative pathway of

- complement: nonenzymatic reversible transition of precursor to active properdin. *J. Immunol.* **118**:525.
12. Podack, E. R., W. P. Kolb, and H. J. Müller-Eberhard. 1976. Purification of the sixth and seventh component of human complement without loss of hemolytic activity. *J. Immunol.* **116**:263.
  13. Kolb, W. P., and H. J. Müller-Eberhard. 1976. The membrane attack mechanism of complement: the three polypeptide chain structure of the eighth component (C8). *J. Exp. Med.* **143**:1131.
  14. Hadding, U., and H. J. Müller-Eberhard. 1969. The ninth component of human complement: isolation, description and mode of action. *Immunology.* **16**:719.
  15. Weber, K., and M. Osborn. 1969. The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. *J. Biol. Chem.* **244**:4406.
  16. Chenoweth, D. E., J. G. Rowe, and T. E. Hugli. A modified method for chemotaxis under agarose. *J. Immunol. Methods.* In press.
  17. Lesavre, P. H., and H. J. Müller-Eberhard. 1978. C3 Proactivator convertase (Factor D). *Fed. Proc.* **37**:1378.
  18. Götze, O. 1975. Proteases of the properdin system. In *Proteases and Biological Control*. E. Reich, D. B. Rifkin and E. Shaw, editors. Cold Spring Harbor Laboratory. 255.
  19. Whaley, K., and S. Ruddy. 1976. Modulation of the alternative complement pathway by  $\beta$ 1H globulin. *J. Exp. Med.* **144**:1147.
  20. Müller-Eberhard, H. J. 1978. Complement: molecular mechanisms, regulation and biologic function. Proc. Dedication Symposium, University of Connecticut Academic Press, New York. In press.
  21. Minta, J. O., and I. H. Lepow. 1974. Studies on the subunit structure of human properdin. *Immunochemistry.* **11**:361.
  22. Nilsson, U., and J. Mapes. 1973. Polyacrylamide gel electrophoresis (PAGE) of reduced and dissociated C3 and C5: studies of the polypeptide chain (PPC) subunits and their modifications by trypsin (Try) and C42-C423. *J. Immunol.* **111**:293.
  23. Bokisch, V. A., M. P. Dierich, and H. J. Müller-Eberhard. 1975. Third component of complement (C3): Structural properties in relation to functions. *Proc. Natl. Acad. Sci. U. S. A.* **72**:1989.
  24. Perrin, L. H., B. S. Joseph, N. R. Cooper, and M. B. A. Oldstone. 1976. Mechanism of injury of virus infected cells by antiviral antibody and complement: participation of IgG, F(ab')<sub>2</sub> and the alternative complement pathway. *J. Exp. Med.* **143**:1027.
  25. Inoue, K., Y. Tanigawa, M. Takubo, J. Satani, and T. Amano. 1959. Quantitative studies on immune bacteriolysis. II. The role of lysozyme in immune bacteriolysis. *Biken J.* **2**:1.
  26. Glynn, A. A., and G. M. Milne. 1967. A kinetic study of the bacteriolytic and bactericidal action of human serum. *Immunology.* **12**:639.